List of Excipients in Branded Drug TRIMETHOBENZAMIDE HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing TRIMETHOBENZAMIDE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Rebel Distributors Corp	trimethobenzamide	21695-448	CELLULOSE, MICROCRYSTALLINE
Rebel Distributors Corp	trimethobenzamide	21695-448	D&C BLUE NO. 1
Rebel Distributors Corp	trimethobenzamide	21695-448	D&C RED NO. 40

What are the Most Frequently-Used Excipients in TRIMETHOBENZAMIDE HYDROCHLORIDE?

# Of NDCs	Excipient
2	ALUMINUM OXIDE
2	AMMONIA
2	BUTYL ALCOHOL

Trimethobenzamide Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 17, 2026

Trimethobenzamide hydrochloride is an established small-molecule antiemetic with limited composition-of-matter exclusivity and a mature oral-capsule market. The strongest commercial opportunities are differentiated generic products: dye-free capsules, vegetarian shells, lower-cost private-label supply, oral liquids for institutional use, and potentially rapidly disintegrating tablets. Regulatory and patent barriers are materially lower than for newer antiemetics, but clinical positioning is constrained by the product label and competition from ondansetron, promethazine, metoclopramide and other antiemetic therapies.

The commercial strategy should prioritize manufacturing reliability, excipient simplification, supply-chain resilience and customer-specific presentations rather than attempting to recreate a premium branded product.

What is trimethobenzamide hydrochloride and how is it marketed?

Trimethobenzamide hydrochloride is an antiemetic indicated for the treatment of nausea and vomiting. The principal marketed dosage form is the 300 mg oral capsule. The historical Tigan product also existed in injectable and rectal dosage forms, but the oral capsule is the clearest current generic-commercial opportunity.

Attribute	Commercial profile
Active ingredient	Trimethobenzamide hydrochloride
Therapeutic class	Antiemetic
Principal oral strength	300 mg capsule
Regulatory status	FDA-approved prescription product
Primary dosage form	Immediate-release hard gelatin capsule
Small-molecule or biologic	Small molecule
Biosimilar exposure	None
Primary market	Generic prescription antiemetic
Key competitors	Ondansetron, promethazine, prochlorperazine, metoclopramide
Main commercial constraint	Lower clinical demand relative to ondansetron and limited differentiation

The product is generally administered in adults at 300 mg three times daily, according to the U.S. prescribing information. The label limits use in certain pediatric settings and states that safety and efficacy have not been established for pediatric patients with gastroenteritis-related vomiting.[1]

What excipients are used in trimethobenzamide hydrochloride capsules?

The marketed 300 mg capsule uses a conventional immediate-release excipient system. Public labeling identifies excipients that may include starch, sucrose, talc, magnesium stearate, colloidal silicon dioxide, pharmaceutical glaze, shellac, titanium dioxide, gelatin and colorants, including FD&C Yellow No. 6, depending on the manufacturer and presentation.[2]

A representative excipient architecture is:

Excipient function	Likely excipient class	Formulation purpose
Diluent or bulking agent	Sucrose, starch or related filler	Achieves capsule fill weight and supports content uniformity
Disintegrant	Starch	Promotes capsule plug breakup after shell dissolution
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate	Reduces tooling friction and capsule-machine adhesion
Opacifier	Titanium dioxide	Controls capsule-shell appearance and opacity
Colorant	FD&C Yellow No. 6 or alternative	Product identification
Capsule shell	Gelatin	Immediate-release capsule delivery
Printing or coating system	Pharmaceutical glaze or shellac	Supports identification and branding

The excipient system is not technically complex. The main development risks are powder flow, blend segregation, capsule-fill variability, dissolution performance and shell compatibility. Because the product is a low-dose-to-moderate-dose capsule rather than a highly potent compound, manufacturers have meaningful latitude to optimize the formulation around cost and patient preferences.

How should manufacturers optimize the excipient system?

A commercially competitive formulation should use the smallest practical number of excipients while preserving content uniformity, dissolution and capsule-machine performance.

Conventional low-cost capsule

A standard generic capsule can use:

• Pregelatinized starch or maize starch as filler and disintegrant
• Colloidal silicon dioxide as glidant
• Magnesium stearate as lubricant
• Hard gelatin shell
• A minimal colorant system

This approach has the lowest development burden and is suitable for retail pharmacy and wholesaler channels. The main manufacturing controls are blend uniformity, lubricant mixing time and capsule-weight variation.

Excessive magnesium stearate can slow wetting and dissolution. Excessive colloidal silicon dioxide can alter powder density and increase dusting. These risks should be evaluated through design-of-experiments work rather than addressed by simply increasing excipient levels.

Dye-free capsule

A dye-free product can remove FD&C Yellow No. 6 and use an uncolored, opaque or natural-color capsule shell. The value proposition is straightforward:

• Avoids sensitivity concerns associated with certain colorants.
• Supports hospital and institutional formularies with excipient restrictions.
• Simplifies global product adaptation.
• Creates a visible distinction from legacy colored capsules.

The principal risk is loss of product recognition. That can be addressed through capsule imprinting, packaging design and a distinct but compliant capsule-shell appearance.

Vegetarian capsule

Hydroxypropyl methylcellulose capsules provide an alternative to gelatin. A vegetarian presentation can support:

• Institutional procurement requirements.
• Religious or dietary preferences.
• Export markets where gelatin source documentation is commercially important.
• Private-label positioning in specialty pharmacy channels.

The change is not automatically equivalent from a manufacturing perspective. HPMC shells can have different moisture behavior, brittleness, dissolution characteristics and machine settings. Comparative dissolution should be evaluated under the applicable immediate-release requirements, including media and agitation conditions relevant to the reference product.

Low-moisture formulation

Trimethobenzamide hydrochloride formulations should be assessed for moisture sensitivity, even where the active ingredient is not highly hygroscopic. Moisture can affect:

• Powder flow.
• Capsule-shell brittleness.
• Disintegration.
• Blend uniformity.
• Long-term assay and impurity performance.

A low-moisture formulation may use an HPMC or gelatin shell selected for water activity control, high-barrier bottles, desiccant-equipped packaging or blister packaging with moisture-resistant foil. Packaging may deliver more commercial value than a complex excipient change because it can reduce stability risk without creating a substantial bioequivalence burden.

What formulations are protected or commercially available for trimethobenzamide hydrochloride?

The most commercially relevant formulation categories are summarized below.

Formulation	Development opportunity	Commercial assessment
300 mg hard gelatin capsule	Generic substitution, cost reduction, dye-free or vegetarian version	Lowest technical risk
300 mg HPMC capsule	Dietary and institutional differentiation	Moderate shell and stability work
Oral solution	Pediatric and swallowing-challenged populations, subject to label limitations	Higher stability, taste and preservative burden
Orally disintegrating tablet	Potential convenience product	Higher taste-masking and bioequivalence risk
Rectal suppository	Historical dosage form	Manufacturing and demand risk
Injection	Historical dosage form with administration and tissue-injury concerns	Weak commercial attractiveness

The capsule is the most defensible first product. An oral liquid may create a secondary opportunity, but it would require a careful assessment of labeled populations, dosing accuracy, preservative selection, palatability and microbial-control requirements. A pediatric liquid would not automatically overcome the label limitation concerning pediatric gastroenteritis-related vomiting.

An orally disintegrating tablet could offer patient convenience, but the active ingredient's taste, tablet loading, moisture sensitivity and rapid-disintegration requirements may increase development cost. A product would need a clear commercial reason to justify that investment.

When does trimethobenzamide hydrochloride lose exclusivity?

Trimethobenzamide hydrochloride is an old small molecule, and the principal U.S. commercial opportunity is generic competition rather than a protected innovator franchise. No biosimilar pathway applies because the product is not a biologic.

The relevant exclusivity framework is:

Exclusivity category	Relevance to trimethobenzamide hydrochloride
New chemical entity exclusivity	Historically expired
Orphan-drug exclusivity	No established current relevance
Pediatric exclusivity	No current commercial barrier identified in the cited sources
Generic 180-day exclusivity	Possible if an ANDA applicant qualifies as a first Paragraph IV filer
Patent-term extension	No material current barrier identified for the legacy oral capsule
Formulation patent	Any enforceable protection would depend on a specific listed or unlisted patent claim
Regulatory exclusivity for biosimilars	Not applicable

The FDA Orange Book is the controlling source for listed patents and approved drug exclusivity. A generic applicant must independently review the current listing for the relevant reference product and strength before filing an ANDA.[3]

What is the Orange Book status of trimethobenzamide hydrochloride?

The commercial profile is consistent with a legacy generic market rather than an active, heavily patented brand market. The Orange Book analysis should focus on:

1. The current reference-listed drug for trimethobenzamide hydrochloride capsules.
2. Any listed method-of-use or formulation patents.
3. The reference product's marketing status.
4. Approved ANDAs and their therapeutic-equivalence codes.
5. Whether a first-filer 180-day exclusivity period remains relevant.

For a mature oral capsule, the most likely patent risk is not a new composition-of-matter patent. It is a formulation, manufacturing or method-of-use claim, if any remains listed and enforceable. A company should not assume that the absence of a visible brand patent eliminates all freedom-to-operate issues. Unlisted patents, contractual restrictions and process patents can still affect manufacturing and launch planning.

Are Paragraph IV challenges relevant to trimethobenzamide hydrochloride?

Paragraph IV risk is likely lower than for recently approved products because trimethobenzamide hydrochloride has been marketed for decades. If a current Orange Book-listed patent exists, an ANDA applicant could certify that the patent is invalid, unenforceable or will not be infringed.

For a legacy product, the likely filing options are:

• Paragraph III certification if an identified patent remains valid.
• Paragraph IV certification if the applicant intends to challenge the patent.
• Paragraph I or II certification where no relevant patent is listed or where patent information is not applicable.

The commercial effect of a Paragraph IV filing would depend on whether the applicant qualifies for 180-day exclusivity and whether the reference sponsor brings an infringement action within the statutory period. The Hatch-Waxman framework can delay approval or launch even when the underlying patent estate is weak.[4]

What patent litigation affects trimethobenzamide hydrochloride?

No major, widely recognized current patent litigation involving the legacy oral trimethobenzamide hydrochloride capsule is evident from the cited FDA and label sources. The litigation profile is therefore materially lower than for high-revenue drugs with active formulation or method-of-use patent programs.

A diligence review should still examine:

• Federal district-court complaints involving the reference-listed drug.
• ANDA litigation under 35 U.S.C. §271(e)(2).
• Consent judgments and launch settlements.
• Patent assignments affecting legacy Tigan intellectual property.
• Manufacturing-process claims involving active pharmaceutical ingredient production.
• State-law claims involving product supply and distribution.

How strong is the patent estate for trimethobenzamide hydrochloride?

The patent estate appears weak from a product-life-cycle perspective because the molecule and core dosage form are old. The stronger barriers are likely operational rather than legal.

Barrier	Relative strength	Business implication
Composition-of-matter patent	Low	Does not support premium pricing
Basic capsule formulation	Low	Easy for generic developers to reproduce
Method-of-use patent	Low to moderate	Depends on narrow indication and claim scope
Manufacturing process	Moderate	Can affect API sourcing and quality consistency
Regulatory know-how	Moderate	Relevant to bioequivalence and stability
Supply reliability	Moderate to high	May create short-term share opportunities
Brand recognition	Low to moderate	Limited protection against substitution

Manufacturing know-how may be more important than patent protection. Consistent API particle size, bulk density, residual solvents, impurity control and capsule-fill performance can determine whether a supplier captures institutional business.

What commercial opportunities exist for trimethobenzamide hydrochloride?

The most credible opportunities are:

Institutional and shortage-driven supply

Hospitals, wholesalers and group purchasing organizations value continuity of supply for older generic antiemetics. A manufacturer with dual API sourcing, validated alternate excipients and adequate safety stock can compete for contracts even without a novel formulation.

Private-label and authorized-generic supply

The product is suitable for private-label arrangements because the formulation is conventional and the therapeutic category is familiar to pharmacists. Opportunities include:

• Pharmacy-chain private labels.
• Regional wholesalers.
• Hospital systems.
• Specialty distributors.
• International licensees.

No prominent current licensing transaction is established in the cited sources. Commercial partnerships are more likely to involve supply, distribution or private-label rights than a high-value innovation license.

Dye-free and vegetarian presentations

These products can support formulary differentiation without creating a new active ingredient. The strongest buyers are institutions with excipient policies, specialty pharmacies and distributors serving dietary-restriction markets.

Multi-source API strategy

A qualified second API source can reduce dependence on a single manufacturer and improve tender competitiveness. The principal technical work involves supplier qualification, impurity comparability, analytical-method transfer and process validation.

Oral-liquid development

An oral liquid could address swallowing difficulties and medication-administration needs in selected adult settings. Its commercial value would depend on label-compliant use, palatability, chemical stability and a practical shelf life. It should not be positioned as a broad pediatric solution without corresponding regulatory support.

How does trimethobenzamide compare with competing antiemetics?

Drug	Main advantage	Main disadvantage versus trimethobenzamide
Ondansetron	Strong demand, broad clinical familiarity, multiple dosage forms	Higher market competition and entrenched prescribing
Promethazine	Low cost and multiple routes	Sedation and anticholinergic effects
Metoclopramide	Useful where gastric motility is relevant	Extrapyramidal and tardive-dyskinesia concerns
Prochlorperazine	Established antiemetic efficacy	Extrapyramidal and sedative effects
Trimethobenzamide	Familiar legacy product and simple capsule manufacturing	Smaller demand and less differentiated clinical positioning

Trimethobenzamide is unlikely to displace ondansetron broadly. Its commercial position is more defensible as a reliable, low-cost alternative in formularies where product availability, price and route selection matter.

What generic launch scenarios exist?

Scenario 1: Conventional capsule launch

This is the lowest-risk pathway. The applicant uses a conventional immediate-release capsule, establishes bioequivalence and competes on price and supply reliability.

Scenario 2: Differentiated capsule launch

A dye-free or vegetarian capsule can create modest differentiation while retaining a familiar dosage form. The product may command limited commercial preference but will remain subject to generic substitution rules.

Scenario 3: Supply-disruption capture

A manufacturer can gain share during competitor shortages if it has validated manufacturing capacity, API inventory and rapid distribution. This strategy requires operational readiness rather than patent protection.

Scenario 4: Oral-liquid or orally disintegrating product

These formats have greater technical and regulatory risk. They may create a niche market, but the expected return is less predictable than for a capsule.

What geographic coverage and manufacturing barriers matter?

U.S. commercialization requires FDA-compliant manufacturing, an approved NDA or ANDA pathway and compliance with current good manufacturing practice. International opportunities depend on country-specific registration, reference-product requirements, excipient acceptability and gelatin or colorant restrictions.

The most important manufacturing barriers are:

• API availability and supplier qualification.
• Control of particle size and bulk density.
• Capsule-fill uniformity.
• Dissolution comparability.
• Moisture control.
• Colorant and shell-source qualification.
• Stability in the intended container-closure system.
• Packaging-line compatibility.

A global formulation should avoid excipients that create country-specific labeling or acceptability problems unless the commercial value justifies the complexity.

Key Takeaways

• Trimethobenzamide hydrochloride is a mature small-molecule antiemetic with the 300 mg capsule as the primary commercial dosage form.
• The core formulation is technically simple and is unlikely to support meaningful patent-based pricing.
• The strongest opportunities are reliable generic supply, private-label distribution, dye-free capsules, vegetarian HPMC capsules and targeted institutional contracts.
• Biosimilar risk does not apply.
• Paragraph IV exposure is likely limited but must be checked against the current Orange Book listing.
• Oral liquids and orally disintegrating tablets offer formulation differentiation but carry higher development, taste, stability and regulatory risk.
• Manufacturing reliability, API sourcing and excipient simplification are more commercially important than an aggressive patent strategy.
• Competitive pressure from ondansetron and other established antiemetics limits the revenue potential of a premium reformulation.

FAQs

Is trimethobenzamide hydrochloride still FDA approved?

Yes. Trimethobenzamide hydrochloride remains an FDA-approved prescription antiemetic, with the 300 mg oral capsule as the principal marketed presentation.[1]

Does trimethobenzamide hydrochloride have biosimilar competition?

No. It is a small-molecule drug. Competition proceeds through the generic drug pathway, not the biosimilar pathway.

Can a company market a dye-free trimethobenzamide capsule?

Potentially, provided the product meets applicable FDA requirements for approval, bioequivalence, stability, labeling and manufacturing controls. Removing a colorant may create commercial differentiation but does not create automatic market exclusivity.

Is trimethobenzamide hydrochloride suitable for an orally disintegrating tablet?

It may be technically feasible, but taste masking, dose loading, moisture protection and rapid-disintegration performance would require substantial development work. The commercial case is weaker than for a conventional capsule unless a clear patient or institutional need is established.

What is the most attractive excipient strategy for a generic manufacturer?

A simplified immediate-release capsule with robust flow, reliable disintegration, low moisture exposure and either dye-free or vegetarian positioning offers the best balance of development cost and commercial differentiation.

References

1. DailyMed. (n.d.). Trimethobenzamide hydrochloride capsule: U.S. prescribing information. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. DailyMed. (n.d.). Trimethobenzamide hydrochloride capsule: Inactive ingredients and product description. National Library of Medicine. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2017). ANDA submissions: Amendments and requests for final approval to tentatively approved ANDAs. FDA Guidance for Industry. https://www.fda.gov/】【。